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The identification of mechanisms that prevent infection with human immunodeficiency virus (HIV) or simian immunodeficiency virus
(SIV) would facilitate the development of an effective AIDS vaccine. In time-course experiments, protection against detectable
superinfection with homologous wild-type SIV was achieved within 21 days of inoculation with live attenuated SIV, prior to the development
of detectable anti-SIV humoral immunity. Partial protection against superinfection was achieved within 10 days of inoculation with live
attenuated SIV, prior to the development of detectable anti-SIV humoral and cellular immunity. Furthermore, co-inoculation of live attenuated
SIV with wild-type SIV resulted in a significant reduction in peak virus loads compared to controls that received wild-type SIV alone. These
findings imply that innate immunity or non-immune mechanisms are a significant component of early protection against superinfection
conferred by inoculation with live attenuated SIV.
D 2004 Elsevier Inc. All rights reserved.
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In simian models of human immunodeficiency virus
(HIV), inoculation with live attenuated simian immunode-
ficiency virus (SIV) elicits potent and durable protection
against superinfection (Almond et al., 1995; Daniel et al.,
1992; Desrosiers, 1990; Lohman et al., 1994; Wyand et al.,
1996). This protection is effective against a diverse range of
variants and multiple routes of infection (Almond et al.,
1995; Cranage et al., 1997; Daniel et al., 1992; Johnson et
al., 1999; Nilsson et al., 1998; Norley et al., 1996; Sharpe et
al., 1997; Wyand et al., 1999). Furthermore, inoculation0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: rstebbings@nibsc.ac.uk (R. Stebbings).with live attenuated SIV can confer protection against
infection with chimeric SIV/HIV (SHIV), in which the env,
tat, vpu and rev genes of SIV have been replaced with those
of HIV, even though this vaccine approach does not elicit
neutralising antibodies against HIV (Bogers et al., 1995;
Dunn et al., 1997; Shibata et al., 1997; Wyand et al., 1999).
However, there are limits to this protection and live
attenuated SIV vaccines have failed to protect against
certain heterologous challenge viruses or failed to protect
against a challenge performed several years post inoculation
(Hofmann-Lehmann et al., 2003; Wyand et al., 1999).
Unfortunately, safety concerns over the stability of attenuat-
ing mutations, which can result in reversion to pathogenicity
in the long-term, have precluded the clinical evaluation of
live attenuated HIV vaccines (Baba et al., 1995; Hofmann-
Lehmann et al., 2003; Ruprecht, 1999; Whatmore et al.,
1995). Nevertheless, if the mechanism(s) of protection04) 249–260
R. Stebbings et al. / Virology 330 (2004) 249–260250conferred by this potent vaccine approach could be
unravelled, then it may facilitate the development of a safe
and effective HIV vaccine. However, there is controversy as
to whether this protection is mediated through acquired
immune responses, innate immunity or non-immune mech-
anisms such as viral interference (Abel et al., 2003; Johnson,
2002; Nixon et al., 2000; Rud et al., 1994b; Stebbings et al.,
2002; Tenner-Racz et al., 2004).
Inoculation with live attenuated SIV has been reported to
elicit a number of acquired anti-SIV immune responses,
including neutralising antibodies (Langlois et al., 1998;
Wyand et al., 1996), cytotoxic T lymphocyte (CTL)
responses (Johnson et al., 1997; Nixon et al., 2000; Vogel
et al., 1998) and helper T cell responses (Gauduin et al.,
1999; Sarkar et al., 2002). Many current HIV vaccine
strategies aim to reproduce these responses. Yet, passive
transfer experiments designed to evaluate the role of
serological responses to inoculation with live attenuated
SIV did not transfer protection (Almond et al., 1997).
However, this contrasts with post-challenge immunotherapy
with immune globulin, purified from the plasma of SIV
infected long-term nonprogressor macaques, which has been
reported to reduce virus burdens and alter disease outcome
(Haigwood et al., 1996). More recently, it has been reported
that infusion of high levels of anti-HIV neutralising
monoclonal antibodies can protect macaques against SHIV
infection (Baba et al., 2000; Ferrantelli et al., 2004; Mascola
et al., 2000, 2003; Parren et al., 2001), although this still
does not account for the protection observed following
inoculation with live attenuated SIV.
With certain SIV vaccine approaches, an inverse
correlation between the precursor frequency of anti-SIV
CTL responses elicited by immunisation and virus load
following challenge has been demonstrated (Gallimore et
al., 1995; Vogel et al., 2002). Furthermore, supporting
evidence for the importance of CD8+ CTL in controlling
SIV infection has been derived from increased plasma
viremia following CD8+ cell depletion of infected macaques
(Jin et al., 1999; Lifson et al., 2001; Metzner et al., 2000;
Schmitz et al., 1999). However, attempts to obtain more
direct evidence by depletion of CD8+ lymphocytes in
attenuated SIVmacC8 vaccinees at the time of challenge
with wild-type SIVmacJ5 failed to abrogate protection
against superinfection, suggesting that factors that control
infection may be distinct from those that protect against
challenge (Stebbings et al., 1998).
One step towards identifying vaccine responses that
confer protection is to perform a time-course study, in order
to identify responses whose appearance correlates with the
development of protection. In time-course experiments, the
onset of protection against heterologous challenge has been
evaluated using several attenuated SIV vaccines, with
varying results. For SIVmac239D3, the earliest reported
protection after vaccination is 8 weeks, when two out of four
vaccinees resisted superinfection with heterologous wild-
type SIV (Wyand et al., 1996). Yet, with SIVmac239Dnefand SIVmacC8, the earliest reported protection after
vaccination is 10 weeks, when two out of four and three
out of four vaccinees resisted superinfection with wild-type
SIV, respectively (Connor et al., 1998; Norley et al., 1996).
Generally, it is accepted that there is a trend towards greater
protection with increased time between inoculation with live
attenuated SIV and subsequent challenge with wild-type
SIV (Connor et al., 1998; Wyand et al., 1996). From these
observations, it has been inferred that increased protection
with time is due to the development or maturation of
acquired anti-SIV immune responses (Cole et al., 1997;
Wyand et al., 1996). Nevertheless, when superinfection at
times early after inoculation occurs, then a significant
reduction in primary viremia compared with naive controls
has been observed (Connor et al., 1998; Stahl-Hennig et al.,
1996). Here we have assessed resistance to superinfection
with homologous wild-type SIVmacJ5 in vaccinees inocu-
lated with live attenuated SIVmacC8 for 70, 42, 21, 10 and
0 days prior to challenge.Results
Time course to protection following inoculation with live
attenuated SIV
Over two studies, we have determined the time interval
between inoculation of live attenuated SIVmacC8 and
challenge with pathogenic, wild-type SIVmacJ5 required to
protect against superinfection. Groups of four cynomolgus
macaques were inoculated in an initial study at either 70,
42 or 21 days prior to challenge (groups A–C, respec-
tively; individuals S169–S180) and, in a subsequent study,
at either 21, 10 or 0 days prior to challenge (groups C–E,
respectively; individuals T317–T328). All vaccinees
(groups A–D) were successfully inoculated with attenuated
SIVmacC8 as determined by virus isolation (Table 1) and
DNA polymerase chain reaction (PCR) (Table 2). At 14
days post challenge, the presence of wild-type SIVmacJ5
was detected by DNA PCR in the peripheral blood
mononuclear cells (PBMC) of all naRve challenge controls
(group F; individuals S181–S184 from the first study and
T329–T332 from the second study) and all co-inoculated
vaccinees (group E; individuals T325–T328). At this time,
apart from a single macaque in group D (T317), there was
no evidence of superinfection with wild-type SIVmacJ5 in
any vaccinees (Table 2). However, further analysis of
lymphoid tissues taken post mortem, between 132 and 168
days post challenge, revealed the presence of wild-type
SIVmacJ5 superinfection in a single vaccinee from group
A (S170) and a total of three vaccinees from group D
(T317, T319 and T320; Table 2). Where superinfection
occurred, then two bands were detected by DNA PCR,
suggesting dual infection with both vaccine and challenge
virus. Formal automated DNA sequencing confirmed
mixed sequence populations, confirming the results of
Table 1
Detectiona and titrationb of infectious virus by co-culture with C8166 cells
Vaccine group and time of
SIVmacC8 inoculation
Animal Viral load (log10 SIV producing cells per 10
6 PBMC)
Days post SIVmacJ5 challenge Post mortemc
70 56 42 28 21 0 14 28 56 84 Bld Spl Mln Pln
(A) Day 70 S169  1.0  n.d.  0.5      +  
S170  1.5 0.5 n.d. 0.5  0.1     +  +
S171  0.5 0.1 n.d.         n.d. 
S172  0.5  n.d.          
(B) Day 42 S173  0.5  0.5        +
S174  0.5 0.5  0.1     + + +
S175  0.5 0.1 0.1 0.1  +     +
S176  1.0 n.d.       +  +
(C) Day 21 S177  0.5 0.1       
S178  1.0 0.5 + + n.d.  + + +
S179  1.0 0.1 + + +  +  
S180     +     
T321  0.1        
T322  0.1 0.1 +      
T323  0.5 0.5  +     
T324  0.1 0.1       +
(D) Day 10 T317  3.0 1.5 + +    n.d. 
T318  1.5 0.1       
T319  2.0 0.1 + +   +  +
T320  3.0 1.0 + + + + + + +
(E) Day 0 T325  1.0 +    +  +
T326  2.0 +   + + + +
T327  1.0 +    +  
T328  1.5 + +   +  +
(F) NaRve controls S181  2.5 + + + + + + +
S182  3.0 + +   + + +
S183  2.5 + + + + + + +
S184  3.0 + +   + + +
T329  2.5 + +     +
T330  3.0 + + + + + + +
T331  2.0 + +   +  +
T332  4.0 + + + + + + +
n.d. denotes that the result was not determined.
a  and + symbols denote negative and positive isolation of infectious virus, respectively, from either 5  106 PBMC or lymphoid tissue cells.
b Virus loads shown are log10 SIV infectious cells per 10
6 PBMC. The detection limit for this assay is log10 0.5 cells per 10
6 PBMC. A value of 0.1 is given
were results were positive by virus isolation but below the detection limit of the titration, where tested.
c Post mortem tissues were taken between days 132 and 168 post SIVmacJ5 challenge. Bld denotes blood. Spl denotes spleen. Mln denotes mesenteric lymph
nodes. Pln denotes peripheral lymph nodes.
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vaccinees from group D, cell-associated virus and plasma
vRNA loads at 14 days post challenge were significantly
lower than amongst challenge controls (group F; Figs. 1A
and B, respectively). Furthermore, amongst co-inoculated
individuals (group E), a significant suppression of cell-
associated virus and plasma vRNA loads was observed 14
days later, when compared with challenge controls that
received wild-type virus alone (group F; Figs. 1A and B,
respectively). Indeed, viral load amongst co-inoculated
individuals (group E) was very similar to controls infected
with SIVmacC8 alone (group G, cell associated virus load
P = 0.7663 and vRNA P = 0.1722, unpaired Student’s t
test, Figs. 1A and B, respectively). Moreover, clearance of
virus-infected cells from the periphery of co-inoculated
individuals (group E) was accelerated compared to
challenge controls (group F) that had received wild-typeSIVmacJ5 alone, as determined by virus isolation (Table 1)
and plasma vRNA analysis (Table 3). Thus, by 56 days
post challenge, it was possible to recover infectious virus
by co-culture of PBMC from all of the challenge controls
(group F) compared with only one out of four co-
inoculated individuals (group E, Table 1).
Detection of vaccine-induced immune responses do not
coincide with early protection
Characterisation of the time interval between inocula-
tion with live attenuated SIVmacC8 and challenge with
pathogenic, wild-type SIVmacJ5 required to protect against
superinfection, provided the opportunity to characterise
vaccine-induced immune responses that coincide with the
onset of protection. On the day of challenge with wild-type
SIVmacJ5, virus-neutralising antibody activity with a titre
Table 2
Detectiona and discriminationb of attenuated SIVmacC8 from wild-type SIVmacJ5
Vaccine group and time of
SIVmacC8 inoculation
Animal Days post SIVmacJ5 challenge Post mortemc
70 56 42 28 21 0 14 28 56 84 Bld Spl Mln Pln
(A) Day 70 S169  + + n.d. + C8 C8 C8 C8 C8 C8 C8 C8 
S170  + + n.d. + C8 C8 C8 C8 C8 C8 C8/J5 C8/J5 C8
S171  + + n.d. + C8 C8 C8 C8 C8 C8 C8 C8 C8
S172  + + n.d. + C8 C8 C8 n.d. C8 C8 C8 C8 C8
(B) Day 42 S173  + + C8 C8 C8 C8 C8 C8 C8 C8 C8
S174  + + C8 C8 C8 C8 C8 C8 C8 C8 C8
S175   + C8 C8 C8 C8 C8 C8 C8 C8 C8
S176   + C8 C8 C8 C8 C8 C8 C8 C8 C8
(C) Day 21 S177  C8 C8 C8 C8 C8 C8 C8 C8 C8
S178  C8 C8 C8 C8  C8 C8 C8 C8
S179  C8 C8 C8 C8 C8 C8 C8 C8 C8
S180  C8 C8 C8 C8  C8 C8 C8 C8
T321  C8 C8 C8 C8 C8 C8 C8 C8 C8
T322   C8   C8 C8 C8 C8 C8
T323  C8 C8 C8  C8 C8 C8 C8 C8
T324   C8   C8 C8 C8  C8
(D) Day 10 T317  C8 C8/J5 C8  C8 C8/J5 n.d. C8 C8/J5
T318  C8 C8 C8  C8 C8 C8 C8 C8
T319  C8 C8 C8 C8  C8/J5 C8 C8 C8/J5
T320   C8 C8  C8 C8/J5 C8/J5 C8/J5 C8/J5
(E) Day 0 T325  C8/J5 C8 C8 C8 C8/J5 C8/J5 n.d. C8/J5
T326  C8/J5 C8/J5  C8/J5 C8/J5 C8/J5 C8/J5 C8/J5
T327  C8/J5 C8/J5  C8 C8/J5 C8/J5 C8/J5 C8/J5
T328  C8/J5 C8 C8 C8 C8/J5 C8/J5 C8/J5 n.d.
(F) NaRve controls S181  J5 J5 J5 J5 J5 J5 J5 J5
S182  J5 J5 J5 J5 J5 J5 J5 J5
S183  J5 J5 J5 J5 J5 J5 J5 J5
S184  J5 J5 J5 J5 J5 J5 J5 J5
T329  J5 J5 J5 J5 J5 J5 J5 
T330  J5 J5 J5 J5 J5 J5 J5 J5
T331  J5 J5 J5 J5 J5 J5 J5 J5
T332  J5 J5 J5 J5 J5 J5 J5 J5
n.d. denotes that the result was not determined.
a  and + symbols denote negative and positive SIV gag DNA PCR, respectively.
b C8 or J5 denote that only SIVmacC8 or SIVmacJ5, respectively, were detected by differential SIV nef PCR. C8/J5 denotes that both SIVmacC8 and
SIVmacJ5 were detected by SIV nef PCR.
c Post mortem tissues were taken between days 132 and 168 post SIVmacJ5 challenge. Bld denotes blood. Spl denotes spleen. Mln denotes mesenteric lymph
nodes. Pln denotes peripheral lymph nodes.
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vaccinated for 70 days (group A) and in half of the
individuals vaccinated for 42 days (group B), but in none
of the individuals vaccinated for 21 days or less (Table 4).
This was not due to any inability of vaccinees to generate
SIV neutralising antibody activity, as titres greater than 1.5
log10 were detected in all individuals by day 84 post
SIVmacJ5 challenge (Table 4). Binding antibody to
recombinant SIV envelope gp130 on the day of challenge
was detected in two out of four vaccinees from group A,
but not in vaccine groups B through F (Table 5). By 140
days post challenge, binding antibodies to recombinant
SIV envelope gp130 could be detected in all vaccinees,
except S171 from group A (Table 5). Binding antibody to
recombinant SIV p27 on the day of challenge was detected
in three out of four vaccinees from group A and two out of
four vaccinees from group B, but not in groups C through
F (Table 6). By 140 days post challenge, bindingantibodies to recombinant SIV p27 could be detected in
all vaccinees (Table 6).
Analysis of cytotoxic T cell responses following inocu-
lation with live attenuated SIVmacC8 was performed on
PBMC from individuals in group C (T321–T323) and
additional subjects W58–W61 and X53–X56. These addi-
tional subjects were all demonstrated to be infected with
SIVmacC8 (data not shown). By chromium release assay,
anti-Nef specific memory CTL responses could be detected
20 days after inoculation of attenuated SIVmacC8 in T321–
T323 (Fig. 2B), but not 10 days after inoculation of W58–
W61 (Fig. 2A). Using intracellular interferon-g (IFNg)
staining of CD3+ CD8+ T cells, significant numbers of
IFNg-positive cells were detected in response to stimulation
with individual 15mer peptides across the Nef protein in
three out of four individuals (X53–X55), tested 19 days after
inoculation with attenuated SIVmacC8 (Fig. 2D). By
comparison, at 10 days post inoculation, an IFNg response
Fig. 1. Virus loads at 14 days post wild-type SIVmacJ5 challenge. (A)
Titration of SIV-producing cells by co-culture. (B) Plasma vRNA loads.
Groups A to E were inoculated with attenuated SIVmacC8 at 70, 42, 21, 10
or 0 days prior to challenge with wild-type SIVmacJ5, respectively. Group
F are naRve controls challenged with wild-type SIVmacJ5. Group G present
virus loads at 14 days post inoculation with attenuated SIVmacC8. Assay
detection limits, denoted by a dashed line, are log10 0.5 cells per 10
6 PBMC
for cell-associated SIV loads and log10 2.3 copies per milliliter of plasma
for SIV RNA loads. The statistical significance of the results was evaluated
individually by unpaired Student’s t test, comparing the result of each
vaccine group with the challenge control group F. Multiple comparison by
Dunnett’s test using an overall error rate of P b 0.05 gives an individual
error rate of P b 0.0097 as significant. Error bars shown are 1 standard
error.
Table 3
Plasma vRNA loadsa post SIVmacJ5 challenge
Vaccine group and time of
SIVmacC8 inoculation
Animal Days post SIVmacJ5 challenge
0 14
(A) Day 70 S169 n.d. b2.3
S170 n.d. b2.3
S171 n.d. b2.3
S172 n.d. b2.3
(B) Day 42 S173 n.d. b2.3
S174 n.d. b2.3
S175 n.d. b2.3
S176 n.d. b2.3
(C) Day 21 S177 n.d. b2.3
S178 n.d. b2.3
S179 n.d. b2.3
S180 n.d. b2.3
T321 2.5 b2.3
T322 2.7 b2.3
T323 2.3 b2.3
T324 n.d. b2.3
(D) Day 10 T317 4.5 3.9
T318 4.3 2.8
T319 4.4 3.0
T320 5.3 3.5
(E) Day 0 T325  4.4
T326  6.1
T327  4.8
T328  4.1
(F) NaRve controls S181  6.9
R. Stebbings et al. / Virology 330 (2004) 249–260 253was only detected to a single Nef 15mer peptide in just one
of these vaccinees, X55 (Fig. 2C).
S182  6.8
S183  6.2
S184  6.3
T329  6.0
T330  6.3
T331  5.5
T332  6.0
n.d. denotes that the result was not determined.
a Virus loads shown are log10 SIV RNA copies per 1 ml of plasma. The
detection limit for this assay is log10 2.3 copies per 1 ml of plasma. Values
below the detection limit of this assay are given as b2.3 for animals positive
by SIV DNA PCR and by the  symbol for animals negative by SIV DNA
PCR.Discussion
This study is part of a series that has characterised
protection conferred by the nef disrupted virus SIVmacC8
(Almond et al., 1995, 1997; Silvera et al., 2001; Stebbings et
al., 1998, 2002). It describes that protection against super-
infection with pathogenic, wild-type SIVmacJ5 can be
obtained within 21 days of inoculation with live attenuated
SIV, at a time when neutralising antibodies were not presentand limited CD8+ T cell responses were detected. Fur-
thermore, it describes blunting of the primary viremia of
wild-type, pathogenic SIVmacJ5 when co-inoculated with
live attenuated SIVmacC8. Thus, the key conclusion of
these observations is that innate immunity or non-immune
mechanisms, such as retroviral interference or target cell
depletion, are likely to contribute to the vaccine protection
observed here.
Failure to identify any correlation between neutralising
antibody responses elicited through inoculation with live
attenuated SIV and the appearance of protection concurs
with previous observations (Almond et al., 1997; Connor et
al., 1998; Langlois et al., 1998; Nilsson et al., 1998; Norley
et al., 1996). Furthermore, our observation of poor
correlation between anti-SIV CTL responses and super-
infection resistance is consistent with the previous findings
of some groups (Nilsson et al., 1998; Nixon et al., 2000;
Stebbings et al., 1998, 2002), but at variance with those of
Table 4
Neutralising antibody titresa post SIVmacJ5 challenge
Vaccine group and time of
SIVmacC8 inoculation
Animal Days post SIVmacJ5 challenge
0 56 84
(A) Day 70 S169 1.5 2.4 n.d.
S170 1.9 2.8 n.d.
S171 1.5 2.1 n.d.
S172 2.5 2.7 n.d.
(B) Day 42 S173  2.7 n.d.
S174  2.5 n.d.
S175 1.8 2.7 n.d.
S176 1.5 3.1 n.d.
(C) Day 21 S177  2.4 n.d.
S178  1.9 n.d.
S179  2.1 n.d.
S180  2.5 n.d.
T321   3.6
T322  1.5 2.4
T323   2.1
T324  1.5 2.8
(D) Day 10 T317  2.7 2.5
T318   1.8
T319  1.8 3.4
T320  1.6 3.6
(E) Day 0 T325  1.9 3.3
T326  3.6 3.9
T327  2.1 3.0
T328  2.5 3.0
(F) NaRve controls S181  2.5 n.d.
S182  2.7 n.d.
S183  2.1 n.d.
S184  2.2 n.d.
T329  2.1 3.0
T330  2.4 2.7
T331  2.4 3.4
T332  3.0 3.4
n.d. denotes that the result was not determined.
a Neutralisation end-point titres are expressed as the reciprocal (log10) of
the highest dilution of antibody, in the serum–virus mixture, that
demonstrates 75% inhibition of the mean p27 antigen production of the
challenge virus controls. Assay cutoff is log10 1.5. Values below the cutoff
are denoted by the  symbol.
R. Stebbings et al. / Virology 330 (2004) 249–260254others (Johnson et al., 1999; Vogel et al., 1998). Never-
theless, here potent early protection against wild-type
SIVmacJ5 challenge was established in a total of eight out
of eight vaccinees within 21 days (group C; two studies) and
in one out of four vaccinees within 10 days (group D; single
study) of inoculation with live attenuated SIVmacC8. In
spite of superinfection of three out of four vaccinees
challenged 10 days after inoculation (group D), replication
of wild-type, pathogenic SIVmacJ5 in those individuals was
effectively contained at or below the level of a non-
pathogenic attenuated SIVmacC8 infection. This super-
infection resistance at 10 days post attenuated SIVmacC8
inoculation was achieved prior to the development of
significant anti-SIV Nef CTL responses, which could not
be detected readily until 19 and 20 days post inoculation.
More intriguing perhaps is the observation of a significant
reduction in peak viral load and shorter primary viremia
following co-inoculation of homologous attenuated SIV-macC8 with wild-type SIVmacJ5, compared with challenge
controls that received wild-type SIVmacJ5 alone. Although
during the first week of infection, the primary viremia of
both attenuated SIVmacC8 and wild-type SIVmacJ5 are
similar, peak vRNA loads between days 10 and 14 are
significantly higher for wild-type virus (Clarke et al., 2003).
Thus, it would appear that competition between attenuated
SIVmacC8 and wild-type SIVmacJ5 during the first week of
co-infection is sufficient to blunt the primary viremia of the
wild-type virus. It is possible that the generation of revertant
virus during co-infection could have contributed to observed
reduction in viremia; however, protection against super-
infection is different to protection against reversion, live
attenuated SIV vaccinees can resist superinfection with
virulent virus but are not protected against the generation of
revertant virus in vivo (Sharpe et al., 1997; Whatmore et al.,
1995). Alternatively, an effective dilution of the wild-type
SIV inoculum in the co-infection experiment may have
produced the observed reduction in primary viremia,
although this would mean that in each macaque there are
only a few thousand susceptible target cells capable of
establishing a persistent infection.
Immunisation with live attenuated SIV is reported to elicit
SIV-specific CD8+ T cells expressing the a4h7 mucosa-
homing receptor, which traffic to the intestinal mucosa
(Cromwell et al., 2000). It could be argued, therefore, that
our inability to detect anti-SIV Nef CTL responses in the
blood of live attenuated SIVmacC8 vaccinees at day 10 post
inoculation is due to their sequestration at sites of initial
infection, such as the intestinal tract (Veazey et al., 1998).
However, it has been demonstrated that anti-SIV CTL
responses develop at a similar rate and magnitude in both
peripheral and mucosal lymphoid tissue during primary SIV
infection (Veazey et al., 2003). Our inability to detect CTL
responses to SIV regulatory proteins at 10 days post SIV
inoculation is in agreement with the observations of others. It
has been reported that anti-SIV gag CTL responses are not
detected at 10 days post SIV inoculation, but arise later
between days 14 and 21 when control of the primary viremia
is first detected (Veazey et al., 2001, 2003). Thus, our
observations would support those of others that CTL
responses can control SIV replication (Jin et al., 1999;
Lifson et al., 2001; Metzner et al., 2000; Schmitz et al.,
1999). However, whether these same immune responses can
also mediate protection against superinfection is not proven
(Stebbings et al., 1998).
Previous studies that have investigated the time interval
between inoculation of live attenuated SIV and challenge
with pathogenic, wild-type SIV required to protect against
superinfection, all used heterologous or uncloned virus for
challenge (Connor et al., 1998; Norley et al., 1996; Wyand
et al., 1996). Here, we have challenged our live attenuated
SIV vaccinees with a wild-type homologous clone. The
advantage of using a homologous challenge to investigate
the underlying mechanism(s) of protection is that it excludes
differences in immunological recognition and tropism for
Table 5
Anti-SIV gp130 antibody titresa following SIVmacC8 inoculation and SIVmacJ5 challenge
Vaccine group and time of
SIVmacC8 inoculation
Animal Days post SIVmacJ5 challenge
70 42 21 10 0 14 28 56 84 140
(A) Day 70 S169    n.d.    2.1 2.2 2.2
S170   2.2 n.d. 2.4 2.3 2.4 2.6 2.4 2.4
S171    n.d.      
S172    n.d. 2.2 2.4 2.4 2.2 2.3 2.3
(B) Day 42 S173   n.d.      2.4
S174   n.d.     2.2 2.3
S175   n.d.     2.0 2.1
S176  n.d. n.d.   2.1 2.3 2.5 2.6
(C) Day 21 S177  n.d.   2.1  2.4 2.3
S178  n.d.   2.2 2.3 2.8 2.7
S179  n.d.     2.1 2.2
S180  n.d.    2.8 2.6 2.6
T321  n.d.  2.0 2.2 2.4 2.7 2.5
T322  n.d.  2.2 2.3 2.6 2.4 2.4
T323  n.d.  1.9 1.9 2.4 2.3 2.1
T324  n.d.   1.6 1.8 1.9 2.0
(D) Day 10 T317   2.0 2.2 2.5 2.5 2.9
T318   1.7 2.3 2.6 2.8 2.9
T319    2.3 3.1 3.2 3.0
T320     2.7 3.0 3.1
(E) Day 0 T325   1.6 2.4 2.4 2.7
T326   2.1 2.6 3.0 3.1
T327   2.1 2.5 2.5 2.6
T328   2.2 2.6 2.9 3.2
(F) NaRve controls S181    2.8 2.6 n.d.
S182    2.4 2.8 n.d.
S183    2.4 2.6 n.d.
S184     2.2 n.d.
T329    2.9 2.8 2.9
T330    2.4 2.5 3.0
T331    2.3 2.7 2.9
T332   2.3 2.4 2.8 3.0
n.d. denotes that the result was not determined.
a End-point titres of anti-SIV gp130 antibodies were calculated by linear regression analysis and expressed as log10 values. Assay cutoff is log10 1.5. Values
below the cutoff are denoted by the  symbol.
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immune response to work and allows identification of the
earliest possible onset of superinfection resistance. Our
findings indicate that the onset of early protection against
superinfection with a homologous challenge occurs
between 10 and 21 days post inoculation with live
attenuated SIVmacC8. Nevertheless, the considerable
resistance to superinfection observed in vaccinees 10 days
post inoculation (group D) and the significant blunting of
the wild-type SIVmacJ5 primary viremia observed follow-
ing co-inoculation (group E) indicates that significant
superinfection resistance arises between 0 and 10 days
post inoculation with live attenuated SIVmacC8. That
partial protection can be established so rapidly implies that
early protection in this model is not based upon acquired
immune mechanisms. Furthermore, similar early detection
of both wild-type and attenuated virus in the lymphoid
organs considered the primary sites of SIV replication
(Canto-Nogues et al., 2001) would suggest that early
resistance to superinfection could be attributed to viral
interference or innate immune responses.The role of CTL responses in mediating the protection
conferred by inoculation with live attenuated immunodefi-
ciency virus vaccines is still controversial. The results
obtained here correlate vaccine protection poorly with CTL
responses, but do not completely rule them out. Further
attempts to correlate protection against challenge with the
appearance of detectable immunity are unlikely to yield
conclusive results. Therefore, alternative approaches should
be pursued. The previous attempt by this group to deplete
CD8+ CTL following inoculation with live attenuated
SIVmacC8 was challenged on the grounds that the degree
of depletion obtained in lymphoid tissues may not have
been sufficient and that the temporal removal of CD8+
effectors would not have prevented the establishment of
effective CD4+ memory T cells that would rapidly drive the
reappearance of CD8+ effectors (Dittmer and Hasenkrug,
1999; Stebbings et al., 1998). The availability of less
immunogenic humanised anti-CD8 monoclonal antibody
that can be administered for longer periods and a model of
protection using live attenuated SIV that would encompass
the period of effective CD8+ cell depletion could make it
Table 6
Anti-SIV p27 antibody titresa following SIVmacC8 inoculation and SIVmacJ5 challenge
Vaccine group and time of
SIVmacC8 inoculation
Animal Days post SIVmacJ5 rechallenge
70 42 21 10 0 14 28 56 84 140
(A) Day 70 S169    n.d. 2.3 2.3 2.3 2.2 2.3 2.3
S170    n.d. 2.2  2.3 2.2 2.3 2.3
S171    n.d.     2.3 
S172    n.d. 2.2 2.4 2.3 2.2 2.7 2.3
(B) Day 42 S173   n.d. 2.2 2.2  2.1  2.2
S174   n.d.  2.2 2.2  2.2 2.3
S175   n.d.     2.2 2.1
S176  n.d. n.d. 2.2 2.3  2.7 2.3 2.4
(C) Day 21 S177  n.d.   2.2 2.1 2.3 2.3
S178  n.d.   2.2 2.3 2.3 2.7
S179  n.d.     2.8 2.3
S180  n.d.    2.3 3.4 2.2
T321  n.d.   2.0 2.3 2.3 2.0
T322  n.d.    1.8 1.9 2.0
T323  n.d.    2.1 1.8 2.2
T324  n.d.     2.0 1.7
(D) Day 10 T317    1.9 2.1 2.3 2.6
T318     2.0 2.5 1.8
T319    1.5 2.4 2.7 2.6
T320     1.9 2.3 2.8
(E) Day 0 T325     1.9 2.2
T326    1.7 2.4 2.5
T327    1.7 2.2 2.3
T328     2.3 2.6
(F) NaRve controls S181   2.2 2.2  n.d.
S182   2.3 2.4 2.8 n.d.
S183    2.1 2.3 n.d.
S184      n.d.
T329    2.3 1.6 2.1
T330     2.7 3.0
T331    2.1 2.8 2.6
T332   2.1 1.6 2.0 2.5
n.d. denotes that the result was not determined.
a End-point titres of anti-SIV p27 antibodies were calculated by linear regression analysis and expressed as log10 values. Assay cutoff is log10 1.5. Values
below the cutoff are denoted by the  symbol.
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Whatever the outcome of this future experiment, the
demonstration here of partial protection 10 days after
inoculation has implicated innate immunity and non-
immune mechanisms as potential components of the
protection conferred by live attenuated SIV vaccines.
Together, our data strongly advocate research into innate
immunity and non-immune mechanisms of protection, in
order that novel prophylactic vaccine approaches can be
developed to safely reproduce the protection conferred by
live attenuated SIV and complements the approaches being
investigated in current clinical trials.Materials and methods
Animals and virus challenges
A total of 52 naRve, D-type retrovirus free, juvenile,
purpose-bred cynomolgus macaques (Macaca fascicularis)
were used in this study. Macaques were housed andmaintained in accordance with United Kingdom Home
Office guidelines for the care and maintenance of nonhuman
primates. The attenuated SIVmac32H (SIVmacC8) virus
clone differs from the wild-type SIVmac32H (SIVmacJ5)
clone by a 12-bp deletion and two nonsynonymous
nucleotide changes, resulting in conservative amino acid
changes in the nef open reading frame (Rud et al., 1994a).
For all live attenuated SIV vaccinations, macaques were
inoculated intravenously with 5000 TCID50 of the 9/90
pool of SIVmacC8, which has an end-point titre of 104
TCID50/ml on C8166 cells (Cranage et al., 1998). For all
wild-type SIV challenges, macaques were inoculated intra-
venously with 500 TCID50 of the J5C stock of SIVmacJ5,
which has an end-point titre of 103 TCID50/ml on C8166
cells (Canto-Nogues et al., 2001).
Experimental outline
In an initial study, attenuated SIVmacC8 inoculation was
carried out in macaques S169–S172, S173–S176 and S177–
S180 at 70, 42 and 21 days before challenge, respectively. In
Fig. 2. Detection of anti-SIV Nef cytotoxic T cell and interferon-g responses
following attenuated SIVmacC8 inoculation. Anti-SIV Nef cytotoxic T cell
responses were assessed by chromium release assay at 10 (A) and 20 (B) days
post SIVmacC8 inoculation, respectively. Solid symbols denote SIVmacC8
inoculated individuals (W58–W61 in A, T321–T323 in B) and empty
symbols denote unvaccinated naRve controls (W62–W65 in A, T329, T330
and T332 in B). SIV Nef specific lysis was deemed significant if greater than
3 standard deviations above the mean response of uninfected controls (8.79%
in A, 6.52% in B), denoted here by a dashed line. Anti-SIV Nef peptide
responses were assessed by intracellular interferon-g staining at 10 (C) and
19 (D) days post inoculation. Anti-SIV Nef peptide responses measured by
intracellular interferon-g staining of gated CD3+ CD8+ PBMC were
considered significant if the percentage of positively stained cells was
greater than 3 standard deviations above background staining of unstimulated
PBMC, denoted here by a dashed line. The mitogens phorbol 12-myristate
13-acetate (PMA) with ionomycin was used as a positive control.
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carried out in macaques T321–T324, T317–T320 and
T325–T328 at 21, 10 and 0 days before challenge,
respectively. Day 0 vaccinees were inoculated intravenously
with a total of 1 ml of pre-mixed vaccine (5000 TCID50 of
SIVmacC8 in 0.5 ml) and challenge virus (500 TCID50 of
SIVmacJ5 in 0.5 ml), for simultaneous infection. Macaques
S181–S184 and T329–T332 were used as naRve challenge
controls in the initial and follow-up study, respectively.
Attenuated SIVmacC8 vaccinees W250–W253 were used as
vaccine virus-only controls (Clarke et al., 2003). For
additional CTL studies, macaques W58–W61 and X53–
X56 were inoculated with attenuated SIVmacC8. Macaques
W62–W65 and X57–X60 were used as uninfected controls
for CTL analysis.Virus detection and quantification
The presence of SIV in PBMC or tissue samples was
determined using SIV gag DNA PCR assays, as previously
described (Rose et al., 1995). The two molecular clones
SIVmacC8 and SIVmacJ5 were differentiated using a nef-
specific nested PCR protocol, encompassing the 12-bp
deletion and subsequent Rsa 1 restriction endonuclease
digestion (Rose et al., 1995). Intermediate revertants lacking
the Rsa 1 restriction site are not distinguished from
SIVmacC8 by this protocol. The overall kinetics of SIV
RNA levels in plasma were determined as previously
described (Clarke et al., 2003). The sensitivity of the assay
is 200 SIV RNA copies per milliliter of plasma. Virus
isolation from PBMC was determined by co-culture with
C8166 cells, and the presence of replicating virus was
confirmed by syncytia identification or by antigen capture at
28 days (Stebbings et al., 1998).
Serology
Neutralising antibody end-point titres were determined as
the dilution of serum in the serum and virus mixture
inhibiting p27 antigen production by at least 75%, expressed
as the log10 of the reciprocal of the end-point dilution (Kent
et al., 1994). Titres of binding antibodies to SIV envelope
gp130 (EVA670 CFAR/NIBSC, Potters Bar, UK) or
recombinant SIV p27 (EVA643 CFAR/NIBSC, Potters
Bar, UK) were determined from heat inactivated (56 8C
for 1 h) plasma samples by ELISA, as previously described
(Almond et al., 1990; Silvera et al., 1994; Stott et al., 1990).
CTL detection by chromium release assay
Autologous targets were prepared by incubating Herpes-
virus papio immortalized B-lymphoblastoid cell lines with 5
PFU/cell of vaccinia virus expressing SIV nef (ARP274,
CFAR/NIBSC, Potters Bar, UK). Effectors were generated
by re-stimulation of PBMC with psoralen/UV inactivated
autologous targets and 10 IU/ml of recombinant human IL-2
for 10 days. Targets pulsed for 2 hours with 50ACi of
51Chromium (Amersham Life Science, Buckinghamshire,
UK) per 1  106 cells were incubated for 5 h at 37 8C + 5%
CO2 with effectors at E:T ratios of 40:1 and 10:1. Super-
natants were collected onto 96-well Lumaplates for reading
on a Topcount scintillation counter (Packard Instruments
BV, Groningen, Netherlands). The percentage specific lysis
was calculated as follows: (experimental release  mini-
mum lysis) / (maximum lysis  minimum lysis) 100.
Spontaneous release from target cells was less than 27% in
all assays.
Intracellular interferon-g detection by flow cytometry
For intracellular cytokine staining isolated PBMC in
RPMI 1640 medium (Gibco BRL, Paisley, UK), supple-
R. Stebbings et al. / Virology 330 (2004) 249–260258mented with 10% foetal calf serum + 50 IU/ml penicillin
streptomycin (Gibco), were incubated overnight with a
range of SIV Nef 15mer peptides at 10 Ag/ml (EVA7067,
CFAR/NIBSC, Potters Bar, UK). One hour into the in-
cubation, monensin, at 2 Ag/ml (Sigma-Aldrich Ltd, Dorset,
UK), was added. Subsequently, PBMC were fixed and
permeabilised with Permeafix (Ortho Diagnostics Systems
Inc.) and stained with anti-monkey CD3 FITC conjugate,
anti-human IFNg PE conjugate and anti-human CD8 PerCP
conjugate, as previously described (Stebbings et al., 2002).
A FACSCalibur cytometer was used for acquisition and data
was analysed using CellQuest Pro software (Becton Dick-
inson, Oxford, UK).Acknowledgments
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